Home›Trial›NCT03301506
🔬NCT03301506Phase 3ACTIVE NOT RECRUITING

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

Study Summary

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Conditions
Primary Biliary Cirrhosis
Interventions / Drugs
Seladelpar 5 mg CapsuleSeladelpar 10 mg Capsule
View on ClinicalTrials.gov ↗
Sponsor
GILD
Gilead Sciences
Antiviral
F24/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.112490+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.